Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 5/20 | 0.50 |
| ▸ | CHRNA7 | P36544 | 12/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1994148 | 0.91 | KIF11 (0.48) | KIF11KCNH2MAPTSMN1; SMN2 | |
| SCHEMBL14124576 | 0.90 | CHRNA7 (0.46) | CHRNA7KCNH2 | |
| SCHEMBL2028099 | 0.89 | KCNH2 (0.48) | CHRNA7KCNH2MAPTSMN1; SMN2 | |
| SCHEMBL14124589 | 0.89 | PKM (0.46) | CHRNA7MAPTSMN1; SMN2 | |
| SCHEMBL12599658 | 0.87 | MAOA (0.42) | MAPTSMN1; SMN2 | |
| SCHEMBL12600344 | 0.85 | PKM (0.48) | CHRNA7KCNH2SMN1; SMN2 | |
| SCHEMBL2036361 | 0.85 | MAOA (0.45) | KIF11CHRNA7KCNH2 | |
| SCHEMBL12601012 | 0.83 | PKM (0.50) | CHRNA7MAPTSMN1; SMN2 | |
| SCHEMBL12600343 | 0.83 | KIF11 (0.48) | KIF11MAPTSMN1; SMN2 | |
| SCHEMBL14124563 | 0.83 | MAOB (0.54) | KCNH2MAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140148432-A1 | Compounds for the Treatment of Neurological Disorders | BABU RUPPA POORNACHARY KAMALESH (US) | 2014-05-29 | — | — | US | disclosed |
| US-20140148432-A1 | Compounds for the Treatment of Neurological Disorders | BABU RUPPA POORNACHARY KAMALESH (US) | 2014-05-29 | — | — | US | disclosed |
| US-8680279-B2 | Compounds for the treatment of neurological disorders | NEUROP, INC. (US) | 2014-03-25 | — | — | US | disclosed |
| US-8680279-B2 | Compounds for the treatment of neurological disorders | NEUROP, INC. (US) | 2014-03-25 | — | — | US | disclosed |
| US-8680279-B2 | Compounds for the treatment of neurological disorders | NEUROP, INC. (US) | 2014-03-25 | — | — | US | disclosed |
| US-20120302543-A1 | Compounds for the Treatment of Neurological Disorders | NEUROP, INC. | 2012-11-29 | — | — | US | disclosed |
| US-20120302543-A1 | Compounds for the Treatment of Neurological Disorders | NEUROP, INC. | 2012-11-29 | — | — | US | disclosed |
| US-20120302543-A1 | Compounds for the Treatment of Neurological Disorders | NEUROP, INC. | 2012-11-29 | — | — | US | disclosed |
| EP-2512241-A1 | COMPOUNDS FOR THE TREATMENT OF NEUROLOGIC DISORDERS | Neurop, Inc. (US) | 2012-10-24 | — | — | EP | disclosed |
| WO-2011075537-A1 | COMPOUNDS FOR THE TREATMENT OF NEUROLOGIC DISORDERS | NEUROP, INC. (US) | 2011-06-23 | — | — | WO | disclosed |
| WO-2011075537-A1 | COMPOUNDS FOR THE TREATMENT OF NEUROLOGIC DISORDERS | NEUROP, INC. (US) | 2011-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120302543-A1 | Compounds for the Treatment of Neurological Disorders | GRIN2A, GRIN2B, GRIN2C | KIF11 1911/4885CHRNA7 79/4885KCNH2 244/4885 |
| US-20140148432-A1 | Compounds for the Treatment of Neurological Disorders | NR2C2, GRIN2C, CNR1 | KIF11 3051/4885CHRNA7 8/4885KCNH2 144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.